Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials - Wikidata - wikimedia - TriplyDB

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

http://www.wikidata.org/entity/Q34542094

about

Acute lung failure The effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program.Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review.Theophylline.Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year.Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation.Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.COPD exacerbations.5: management.Management of acute ventilatory failure.Treating COPD with PDE 4 inhibitors.The Saudi Guidelines for the Diagnosis and Management of COPD.Safety of chronic obstructive pulmonary disease medications: a primary care perspective.Assessment and management of chronic obstructive pulmonary disease in the emergency department and beyond.Blood reflects tissue oxidative stress: a systematic review.Pharmacotherapy for the treatment of asthma: current treatment options and future directions.Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.Doxofylline and theophylline: a comparative clinical study Aminophylline for treating asthma and chronic obstructive pulmonary disease.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.[Diagnosis and therapy of COPD exacerbation].Treatment of chronic obstructive pulmonary disease in hospitalized geriatric patients.

P2860

Q26852173-1B38D879-21A5-44F7-975A-0A5259641400 Q30820703-40164AE2-8F6F-4838-8FFC-F68F91F05A31 Q33491797-D8E6AC57-6939-417D-8AEB-9C19AF7BF956 Q33664235-B44C29A1-3CB1-4EE1-87FD-E70AD37BE7F8 Q34039712-2E8424F2-CE31-40DB-B5EB-F5C125C5AC11 Q34550471-921AE4D4-DBD8-4B0A-80CC-3E44A1FF59EC Q34558280-F0183526-6916-4195-B74F-44819A9D4DD7 Q35520406-2562EB33-5767-4D62-80A6-337E9CD7AB75 Q35537967-1478EA4D-6BC6-4E08-878D-74C830678B21 Q35733010-8FA5B4F0-8F24-4540-A7DB-7345484353E7 Q36203144-F3489101-993F-4424-B2C1-399AE8AC1C0E Q36528234-DEF729D0-2DDA-4B88-A945-0261191D08E8 Q37082594-B3D80748-F7E3-415A-A9B5-583B66164B54 Q37733309-A83D4E46-2D85-4B18-8F80-E69BEE3ED283 Q37874890-7A12447E-D1F4-4420-9E35-D1EEEFB0476F Q37920898-20A1C870-65E4-419B-BB78-9C6D5178EB6F Q38315996-B67A1BCE-C9DD-4393-BF79-7363C9551C0B Q38579908-795C05B3-0E6E-482D-AE4E-0CEF1C02EAD1 Q38595360-3286AF62-A514-4022-AC7B-08EB2DAD8ABF Q42685594-12F934C0-F697-49BD-B539-FCCAA33579E0 Q43061672-8B704773-03D1-470A-86B2-E61C7300B143 Q47984024-6A743924-5E34-4642-9564-BCA9390F6925 Q52888876-9974F700-F3AD-4A9A-B002-89B882CBCEB0 Q53557980-C1C053AD-50B2-4601-AAF2-67216195B60D

P2860

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

http://www.wikidata.org/entity/Q34542094

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Methylxanthines for exacerbati ...... -analysis of randomised trials

@ast

Methylxanthines for exacerbati ...... -analysis of randomised trials

@en

Methylxanthines for exacerbati ...... -analysis of randomised trials

@nl

type

label

Methylxanthines for exacerbati ...... -analysis of randomised trials

@ast

Methylxanthines for exacerbati ...... -analysis of randomised trials

@en

Methylxanthines for exacerbati ...... -analysis of randomised trials

@nl

prefLabel

Methylxanthines for exacerbati ...... -analysis of randomised trials

@ast

Methylxanthines for exacerbati ...... -analysis of randomised trials

@en

Methylxanthines for exacerbati ...... -analysis of randomised trials

@nl

P1433

Q34542094-DC1F4C58-0DFA-4E87-A34E-F05B1A92E2F3

P1476

Q34542094-644B4673-DED4-45F5-BE89-B95B5268BB5E

P2093

Q34542094-DBF79819-12E5-4CF4-BEFC-76718A7AB90B

Q34542094-EED9C8BA-47B1-4FD1-8E7E-1BC83831BF4B

P2860

Q34542094-04DF8D80-31D4-4591-8A7E-10E56AD5C762

Q34542094-14909B49-304B-4F53-BA08-E1572C5502DA

Q34542094-21047387-D0F8-494B-9D8F-CE608E0DC8CB

Q34542094-3C36D586-0213-41CC-B421-47B0E206FA66

Q34542094-44DBD492-0BFB-4AF7-A3FD-F3D5A3E2B24A

Q34542094-537DBF68-01C4-4F06-A78E-BD37F5609276

Q34542094-5A524BCA-170C-40C6-85AD-58BB679A10DA

Q34542094-847C2D2D-020F-4CD8-B392-AF3896727803

Q34542094-9F740868-7DA0-4C2B-8E4E-8B311649318E

Q34542094-B367A974-88A3-4E4D-8E96-BE285C1FF37F

P304

Q34542094-BDC16B11-933E-4B36-80C8-A09BE8DE2E8C

P31

Q34542094-426A25AF-109E-49DB-B719-81714928DE60

Q34542094-ec6fe3a7-7dbd-4b8c-8a70-d47aa41e9d61

P356

Q34542094-90691AA9-0ECF-4738-A295-C1E6769F2577

P407

Q34542094-9E3D2645-184C-46F0-9CF4-8171406AB8EE

P433

Q34542094-ED81CC44-FDDE-42E0-AEB0-0876849FBE22

P478

Q34542094-5981DF0D-F986-46CF-B506-B44FE0447460

P50

Q34542094-DDF7C3EA-7A85-4F84-9839-2E76CAE99842

P577

Q34542094-D8DC6EA7-66E1-4495-9B90-15BB51C5A7D3

P5875

Q34542094-84372E94-711F-40C4-857D-15FB80141464

P698

Q34542094-95B1C352-A26B-4E50-84FE-F69C75799F56

P921

Q34542094-62FEF69E-4E83-4947-BFE1-B9B3FFF93C74

Q34542094-9555A2AB-0BA7-454E-9143-5CDF6E642669

P932

Q34542094-4E1BBEF8-BDCA-4B0E-908E-C0B6183998AA

P356

BMJ.327.7416.643

P1433

P1476

Methylxanthines for exacerbati ...... -analysis of randomised trials

@en

P2093

Carlos A Camargo

http://www.w3.org/2001/XMLSchema#string

R Graham Barr

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force.

Oral theophylline for chronic obstructive pulmonary disease.

Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease.

Rapid assay of serum theophylline levels.

Theophylline in asthma.

[The effect of an oral aminophylline compound with protracted activity on respiratory resistance and blood gases in obstructive respiratory diseases (author's transl)]

A double-blind comparison of a microcrystalline theophylline tablet and salbutamol in reversible airways obstruction.

Aminophylline therapy for acute bronchospastic disease in the emergency room.

P304

643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.327.7416.643

http://www.w3.org/2001/XMLSchema#string

P407

P433

7416

http://www.w3.org/2001/XMLSchema#string

P478

327

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9088972

http://www.w3.org/2001/XMLSchema#string

P698

14500434

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

196388

http://www.w3.org/2001/XMLSchema#string